TY - JOUR
T1 - Effects of pancuronium bromide on cerebral blood flow changes during seizures in newborn pigs
AU - Pourcyrous, Massroor
AU - Leffler, Charles W.
AU - Bada, Henrietta S.
AU - Korones, Sheldon B.
AU - Stidham, Gregory L.
AU - Busija, David W.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1992/6
Y1 - 1992/6
N2 - We investigated the effects of pancuronium bromide pretreatment on cerebral blood flow (CBF) during bicuculline-induced seizures in anesthetized piglets. Arterial blood pressure, gases, pH, cerebral electrocortical activity, and CBF (radioactive microsphere) were monitored at baseline, 10 min after administration of pancuronium (0.3 mg/kg i.v.; n — 9) or vehicle (normal saline; n = 8), and again at 5, 15, and 60 min after bicuculline (3 mg/ kg i.v.). No change in CBF from baseline was observed at 10 min after either saline or pancuronium treatment, before induction of seizures. In the saline group, CBF was 36 ± 3 mL- min"' -100 g' before bicuculline and increased to 166 ± 24 and 205 ± 35 mLmin'100 g' at 5 and 15 min, respectively, after bicuculline, returning toward baseline by 60 min. In the pancuronium group at 5 min after bicuculline, CBF increased from 45 ± 7 to 169 ± 26 mL-min1 100 g', but fell to 88 ± 17 mL min '100 g ' at 15 min in contrast to saline-treated piglets. Also, at 15 min of seizures, differences between groups were observed in arterial blood pressure, gases, and pH. Although these variables were in the normal range with pancuronium treatment, the saline-treated animals had increased arterial blood pressure (81 ± 6 mm Hg) and Pco2 (6 ± 0.4 kPa) and decreased Po2 (7 ± 0.5 kPa) and pH (6.91 ± 0.06). Electrocortical activity was abnormal during seizures in both groups. At 60 min, reversal to normal activity was observed in six of nine pancuronium-treated animals versus two of eight saline-treated animals. These data suggest that pancuronium limits cerebral hyperemia during prolonged seizures by attenuating increases in blood pressure as a result of elimination of skeletal muscle activity. This leads to minimal alteration of arterial Pco2, Po2, and pH during seizures.
AB - We investigated the effects of pancuronium bromide pretreatment on cerebral blood flow (CBF) during bicuculline-induced seizures in anesthetized piglets. Arterial blood pressure, gases, pH, cerebral electrocortical activity, and CBF (radioactive microsphere) were monitored at baseline, 10 min after administration of pancuronium (0.3 mg/kg i.v.; n — 9) or vehicle (normal saline; n = 8), and again at 5, 15, and 60 min after bicuculline (3 mg/ kg i.v.). No change in CBF from baseline was observed at 10 min after either saline or pancuronium treatment, before induction of seizures. In the saline group, CBF was 36 ± 3 mL- min"' -100 g' before bicuculline and increased to 166 ± 24 and 205 ± 35 mLmin'100 g' at 5 and 15 min, respectively, after bicuculline, returning toward baseline by 60 min. In the pancuronium group at 5 min after bicuculline, CBF increased from 45 ± 7 to 169 ± 26 mL-min1 100 g', but fell to 88 ± 17 mL min '100 g ' at 15 min in contrast to saline-treated piglets. Also, at 15 min of seizures, differences between groups were observed in arterial blood pressure, gases, and pH. Although these variables were in the normal range with pancuronium treatment, the saline-treated animals had increased arterial blood pressure (81 ± 6 mm Hg) and Pco2 (6 ± 0.4 kPa) and decreased Po2 (7 ± 0.5 kPa) and pH (6.91 ± 0.06). Electrocortical activity was abnormal during seizures in both groups. At 60 min, reversal to normal activity was observed in six of nine pancuronium-treated animals versus two of eight saline-treated animals. These data suggest that pancuronium limits cerebral hyperemia during prolonged seizures by attenuating increases in blood pressure as a result of elimination of skeletal muscle activity. This leads to minimal alteration of arterial Pco2, Po2, and pH during seizures.
UR - http://www.scopus.com/inward/record.url?scp=0026538118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026538118&partnerID=8YFLogxK
U2 - 10.1203/00006450-199206000-00019
DO - 10.1203/00006450-199206000-00019
M3 - Article
C2 - 1635828
AN - SCOPUS:0026538118
SN - 0031-3998
VL - 31
SP - 636
EP - 639
JO - Pediatric Research
JF - Pediatric Research
IS - 6
ER -